Tag Archives: Brilique

Two 'Most Promising' New Drugs Face Setbacks in US

Two of the drugs named “most promising” in Thomson Reuters’ recent quarterly report hit snags in the US, despite European approval. Those two products – AstraZeneca’s Brilique (Brilinta in the US), a blood thinner, and Pharming’s Ruconest (Rhucin in the US) – were held up during FDA’s review process. Brilique (ticagrelor), AstraZeneca’s leading pipeline drug, […]
Posted in FDA, Global, R&D, Regulatory, Sales | Also tagged , , , , | Leave a comment
  • Categories

  • Meta